DE60025905D1 - In vitro methode zur synchronisation von oozytenreifung - Google Patents

In vitro methode zur synchronisation von oozytenreifung

Info

Publication number
DE60025905D1
DE60025905D1 DE60025905T DE60025905T DE60025905D1 DE 60025905 D1 DE60025905 D1 DE 60025905D1 DE 60025905 T DE60025905 T DE 60025905T DE 60025905 T DE60025905 T DE 60025905T DE 60025905 D1 DE60025905 D1 DE 60025905D1
Authority
DE
Germany
Prior art keywords
synchronization
vitro method
oxygen treatment
oxygen
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60025905T
Other languages
English (en)
Other versions
DE60025905T2 (de
Inventor
Christian Grondahl
Host Hansen
Alexander Ruebig
Christa Hegele-Hartung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE60025905D1 publication Critical patent/DE60025905D1/de
Publication of DE60025905T2 publication Critical patent/DE60025905T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
DE60025905T 1999-02-24 2000-02-23 In vitro methode zur synchronisation von oozytenreifung Expired - Fee Related DE60025905T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK25599 1999-02-24
DKPA199900255 1999-02-24
US13081699P 1999-04-23 1999-04-23
US130816P 1999-04-23
DK131099 1999-09-16
DKPA199901310 1999-09-16
PCT/DK2000/000074 WO2000050066A1 (en) 1999-02-24 2000-02-23 Treatment of infertility

Publications (2)

Publication Number Publication Date
DE60025905D1 true DE60025905D1 (de) 2006-04-20
DE60025905T2 DE60025905T2 (de) 2006-09-14

Family

ID=27220546

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60025905T Expired - Fee Related DE60025905T2 (de) 1999-02-24 2000-02-23 In vitro methode zur synchronisation von oozytenreifung

Country Status (13)

Country Link
US (1) US6585982B1 (de)
EP (1) EP1156822B1 (de)
JP (1) JP2002537349A (de)
KR (1) KR20010093280A (de)
CN (1) CN1353617A (de)
AT (1) ATE317266T1 (de)
AU (1) AU2794100A (de)
BR (1) BR0008468A (de)
CZ (1) CZ20012967A3 (de)
DE (1) DE60025905T2 (de)
ES (1) ES2258445T3 (de)
HU (1) HUP0200157A3 (de)
WO (1) WO2000050066A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
WO2000052142A2 (en) * 1999-02-26 2000-09-08 Novo Nordisk A/S Culture medium comprising meiosis activating sterols (mas) and method for in vitro fertilisation
AU3376501A (en) * 2000-02-25 2001-09-03 Novo Nordisk A/S Improvement of implantation rate
WO2001062258A2 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate using ff-mas
JP2003533222A (ja) * 2000-05-18 2003-11-11 シエーリング アクチエンゲゼルシャフト 経年卵母細胞の受精
US6995252B2 (en) * 2000-05-25 2006-02-07 Queen's University At Kingston PT32 sperm protein, sperm c-Yes, oocyte cytoplasmic c-Yes and uses thereof
EP1216701A1 (de) * 2000-12-22 2002-06-26 Schering Aktiengesellschaft Verfahren zur Erhöhung der Konzentration von Meiosis-aktivierenden Sterolen in der Cholesterolsynthese und die Verwendung von potenten Hemmstoffen in das Verfahren
EP1245572A1 (de) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol-Verbindungen, ihre Verwendung zur Herstellung Meiose-regulierender Medikamenten und ein Vefahren zu ihrer Herstellung
MEP38708A (en) 2001-09-12 2011-02-10 Merck Serono Sa Use of hcg and lh in controlled ovarian hyperstimulation
IL160780A0 (en) 2001-09-12 2004-08-31 Applied Research Systems USE OF hCG IN THE MANUFACTURE OF A MEDICAMENT
AU2002324183B2 (en) * 2001-09-12 2007-10-25 Merck Serono Sa Use of hCG and LH in controlled ovarian hyperstimulation
AU2003203145A1 (en) * 2002-02-22 2003-09-09 Novo Nordisk A/S A transducer of mas signalling
US20050208651A1 (en) 2002-03-08 2005-09-22 Ri-Cheng Chian Vitro maturation of immature human oocytes
EP1511537B1 (de) * 2002-06-07 2012-11-21 Ares Trading S.A. Verfahren zur konstrollierten ovariellen hyperstimulation und pharmazeutisches set zur verwendung bei diesem verfahren
SI1765085T1 (sl) 2004-05-17 2015-11-30 The General Hospital Corporation Sestavki, ki vsebujejo ženske zarodne matične celice in postopki njihove uporabe
EP2422794A3 (de) 2006-03-07 2013-03-13 Geeta Shroff Zusammentsetzungen enhaltend menschliche embryonale Stammzellen und ihre Derivate, Verwendung davon und Verfahren zur ihrer Vorbereitung
US8647869B2 (en) 2011-04-14 2014-02-11 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
WO2013002880A1 (en) 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563059A (en) * 1993-02-23 1996-10-08 Genentech, Inc. Use of human inhibin and human activin to increase the number of mature primate oocytes
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols
CA2214126A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
AU6122696A (en) * 1995-06-23 1997-01-22 Novo Nordisk A/S Meiosis regulating compounds
HUP9900454A3 (en) * 1995-06-23 1999-11-29 Novo Nordisk As Meiosis regulating compounds and their use
HUP9904616A3 (en) * 1996-12-20 2001-02-28 Novo Nordisk As Meiosis regulating cholestane-derivatives
PL337188A1 (en) * 1997-06-04 2000-08-14 Akzo Nobel Nv Derivatives of 17beta - allyloxy (thio) alkyl - androstane for modulation of meiosis
US5866599A (en) * 1997-06-06 1999-02-02 Basf Aktiengesellschaft Fungicidal mixtures
ES2286008T3 (es) * 1999-02-24 2007-12-01 Novo Nordisk A/S Tratamiento de la infertilidad.

Also Published As

Publication number Publication date
HUP0200157A3 (en) 2002-06-28
ATE317266T1 (de) 2006-02-15
US6585982B1 (en) 2003-07-01
HUP0200157A2 (hu) 2002-05-29
KR20010093280A (ko) 2001-10-27
AU2794100A (en) 2000-09-14
DE60025905T2 (de) 2006-09-14
BR0008468A (pt) 2002-02-05
CZ20012967A3 (cs) 2001-12-12
EP1156822B1 (de) 2006-02-08
ES2258445T3 (es) 2006-09-01
WO2000050066A1 (en) 2000-08-31
EP1156822A1 (de) 2001-11-28
CN1353617A (zh) 2002-06-12
JP2002537349A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
DE60025905D1 (de) In vitro methode zur synchronisation von oozytenreifung
ATE361977T1 (de) In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen
DE60114002D1 (de) VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
SG148217A1 (en) Method for treating adamts-5-associated disease
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
BR0109975A (pt) Método para produzir ansamitocinas
DE50105968D1 (de) VERFAHREN ZUR HERSTELLUNG VON AlKYLVERBRÜCKTEN LIGANDSYSTEMEN UND ÜBERGANGSMETALLVERBINDUNGEN
NO984950L (no) Forbindelser med veksthormonfrigj°rende egenskaper
MY141020A (en) Novel pparalpha and ppargamma agonists
ATE294771T1 (de) Mikrobielles verfahren zur herstellung von pravastatin
GB9907571D0 (en) Compounds
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
DE50015890D1 (de) Verfahren zur synchronisation
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
IS5380A (is) Aðferð til framleiðslu á vaxtarhormón seyti
ATE306942T1 (de) Zusammensetzung zur in-vitro befruchtung
ATE446952T1 (de) Herstellungsverfahren von 2-cyanopyridinen
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
NO20015285L (no) Fremstillingsprosess for n¶ringsmiddelfermenterende midler
ATE466847T1 (de) Verfahren zur herstellung von 14-beta- hydroxybaccatin-iii-1,14-carbonat
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
ATE306521T1 (de) Polycarbonat-substrate
EE200100242A (et) Alfa-arüülalkaanhapete valmistamismeetod

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee